DRUG POLICY OF THE EUROPEAN UNION SIVIGLIA 15 May 2007 SILVIO GARATTINI.
Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial Journal Club General.
